ATE323702T1 - Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität - Google Patents

Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität

Info

Publication number
ATE323702T1
ATE323702T1 AT03766443T AT03766443T ATE323702T1 AT E323702 T1 ATE323702 T1 AT E323702T1 AT 03766443 T AT03766443 T AT 03766443T AT 03766443 T AT03766443 T AT 03766443T AT E323702 T1 ATE323702 T1 AT E323702T1
Authority
AT
Austria
Prior art keywords
tie2
tek
pyrimidines
activity
condensed pyridines
Prior art date
Application number
AT03766443T
Other languages
English (en)
Inventor
Richard William Arthur Luke
Clifford David Jones
William Mccoull
Barry Raymond Hayter
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB0218168A external-priority patent/GB0218168D0/en
Priority claimed from GB0312356A external-priority patent/GB0312356D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE323702T1 publication Critical patent/ATE323702T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AT03766443T 2002-08-06 2003-08-01 Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität ATE323702T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0218168A GB0218168D0 (en) 2002-08-06 2002-08-06 Compounds
GB0312356A GB0312356D0 (en) 2003-05-30 2003-05-30 Compounds

Publications (1)

Publication Number Publication Date
ATE323702T1 true ATE323702T1 (de) 2006-05-15

Family

ID=31497259

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03766443T ATE323702T1 (de) 2002-08-06 2003-08-01 Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität

Country Status (15)

Country Link
US (1) US7427616B2 (de)
EP (1) EP1537112B1 (de)
JP (1) JP2005538118A (de)
KR (1) KR20050067383A (de)
AR (1) AR041189A1 (de)
AT (1) ATE323702T1 (de)
AU (1) AU2003246972A1 (de)
BR (1) BR0313078A (de)
CA (1) CA2494421A1 (de)
DE (1) DE60304718T2 (de)
IL (1) IL166521A0 (de)
MX (1) MXPA05001389A (de)
NO (1) NO20050418L (de)
TW (1) TW200407116A (de)
WO (1) WO2004013141A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0230089D0 (en) * 2002-12-24 2003-01-29 Astrazeneca Ab Therapeutic agents
MXPA06005578A (es) * 2003-11-17 2006-08-11 Pfizer Prod Inc Compuestos de pirrolopirimidina utiles en el tratamiento del cancer.
TWI332003B (en) 2004-01-30 2010-10-21 Lilly Co Eli Kinase inhibitors
GB0402518D0 (en) * 2004-02-05 2004-03-10 Astrazeneca Ab Therapeutic agents
CN1922151A (zh) * 2004-02-12 2007-02-28 特兰斯泰克制药公司 取代的吡咯衍生物、组合物和使用方法
WO2005105803A2 (en) * 2004-04-28 2005-11-10 Cv Therapeutics, Inc. Purine derivatives as a1 adenosine receptor antagonists
MXPA06013805A (es) 2004-05-27 2007-02-02 Pfizer Prod Inc Derivados de pirrolopirimidina de utilidad en el tratamiento contra el cancer.
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate
WO2006019965A2 (en) * 2004-07-16 2006-02-23 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
BRPI0514094A (pt) * 2004-08-02 2008-05-27 Osi Pharm Inc composto, composição, e, método de tratamento de distúrbio hiperproliferativo
SG155222A1 (en) 2004-08-13 2009-09-30 Genentech Inc Thiazole based inhibitors of atp-utilizing enzymes
EP1858877B1 (de) 2005-01-14 2014-03-12 Gilead Connecticut, Inc. 1,3-substituierte diaryl-harnstoffe als modulatoren von kinase-aktivität
MX2008008320A (es) * 2005-12-23 2008-09-03 Smithkline Beecham Corp Inhibidores de azaindol de aurora cinasas.
CA2649543A1 (en) 2006-04-21 2007-11-01 Amgen Inc. Thieno-[2,3-d]pyrimidine and thieno-pyridazine compounds and methods of use
WO2008057280A1 (en) 2006-10-27 2008-05-15 Amgen Inc. Multi-cyclic compounds and methods of use
EP2247596A2 (de) 2008-01-11 2010-11-10 Natco Pharma Limited Neuartige pyrazol-[3,4-d-]pyrimidin-derivate als wirkstoffe gegen krebs
CA2729012A1 (en) 2008-06-27 2009-12-30 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
CA2731228A1 (en) 2008-07-22 2010-01-28 Biocryst Pharmaceuticals, Inc. Synthetic intermediates and processes
JOP20190230A1 (ar) 2009-01-15 2017-06-16 Incyte Corp طرق لاصلاح مثبطات انزيم jak و المركبات الوسيطة المتعلقة به
WO2011018894A1 (en) * 2009-08-10 2011-02-17 Raqualia Pharma Inc. Pyrrolopyrimidine derivatives as potassium channel modulators
US8722660B2 (en) 2010-02-17 2014-05-13 Takeda Pharmaceutical Company Limited Heterocyclic compound
EP2603216A4 (de) * 2010-08-11 2013-12-18 Millennium Pharm Inc Heteroaryle und verwendungen davon
DK2614052T3 (en) 2010-09-08 2015-04-07 Bristol Myers Squibb Co PIPERAZINE ANALYSIS UNKNOWN AS WIDE-SPECTIFIED ANTIVIRAL INFLUENZAMENTS
EA201390476A1 (ru) 2010-09-28 2013-08-30 Бристол-Майерс Сквибб Компани Новые пиперазиновые аналоги с замещенными гетероарильными группами в качестве противовирусных средств широкого применения против гриппа
US9925193B2 (en) 2012-11-20 2018-03-27 Proqinase Gmbh Thioether derivatives as protein kinase inhibitors
EP2733146A1 (de) * 2012-11-20 2014-05-21 KTB Tumorforschungsgesellschaft mbH Thioetherderivate als Proteinkinase-Inhibitoren
MX2016000669A (es) 2013-07-15 2016-11-11 Basf Se Compuestos plaguicidas.
EP3039020B1 (de) * 2013-08-27 2017-07-19 Bristol-Myers Squibb Company Ido-hemmer
WO2016100495A1 (en) * 2014-12-17 2016-06-23 Duquesne University Of The Holy Spirit CONFORMATIONALLY RESTRICTED 4-SUBSTITUTED-2,6-DIMETHYLFURO[2,3-d]PYRIMIDINES AS ANTITUMOR AGENTS
EP3632908A1 (de) 2018-10-02 2020-04-08 Inventiva Inhibitoren der yap / taz-tead-interaktion und ihre verwendung bei der behandlung von krebs
AU2019385480B2 (en) * 2018-11-20 2025-04-24 Georgetown University Compositions and methods for treating neurodegenerative, myodegenerative, and lysosomal storage disorders
EP4553080A1 (de) 2023-11-07 2025-05-14 Ustav Organicke Chemie a Biochemie AV CR, v.v.i. Nucleosidderivate als antivirale mittel gegen coronaviren

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DD287503A5 (de) 1988-06-13 1991-02-28 Karl-Marx-Universitaet Leipzig,De Verfahren zur herstellung von 4-amino-2-mercapto-thieno-/2,3-d/pyrimidinen bzw. 4-amino-2-alkylthio-thieno/2,3-d/-pyrimidinen
DE4008726A1 (de) 1990-03-19 1991-09-26 Basf Ag Thieno(2,3-d)pyrimidinderivate
US5958930A (en) * 1991-04-08 1999-09-28 Duquesne University Of The Holy Ghost Pyrrolo pyrimidine and furo pyrimidine derivatives
US6756388B1 (en) 1993-10-12 2004-06-29 Pfizer Inc. Benzothiophenes and related compounds as estrogen agonists
US5589482A (en) 1994-12-14 1996-12-31 Pfizer Inc. Benzo-thiophene estrogen agonists to treat prostatic hyperplasia
AU6966696A (en) 1995-10-05 1997-04-28 Warner-Lambert Company Method for treating and preventing inflammation and atherosclerosis
AR004010A1 (es) * 1995-10-11 1998-09-30 Glaxo Group Ltd Compuestos heterociclicos
WO1997049706A1 (en) 1996-06-25 1997-12-31 Novartis Ag SUBSTITUTED 7-AMINO-PYRROLO[3,2-d]PYRIMIDINES AND THE USE THEREOF
CA2263838A1 (en) 1996-08-21 1998-02-26 Sugen, Inc. Crystal structures of a protein tyrosine kinase
JP2001516353A (ja) 1997-03-19 2001-09-25 ビーエーエスエフ アクチェンゲゼルシャフト ピロロ［２，３ｄ］ピリミジンおよびチロシンキナーゼ阻害剤としてのこれらの使用
US6413975B1 (en) 1999-04-02 2002-07-02 Euro-Celtique, S.A. Purine derivatives having phosphodiesterase iv inhibition activity
ID23978A (id) 1997-11-11 2000-06-14 Pfizer Prod Inc Turunan-turunan tienopirimidin dan tienopiridin yang berguna sebagai zat-zat anti kangker
CA2331878A1 (en) 1998-05-14 1999-11-18 G.D. Searle & Co. 1,5-diaryl substituted pyrazoles as p38 kinase inhibitors
JP2002517396A (ja) 1998-06-04 2002-06-18 アボット・ラボラトリーズ 細胞接着阻害抗炎症性化合物
SE9802729D0 (sv) 1998-08-13 1998-08-13 Astra Pharma Prod Novel Compounds
PL346700A1 (en) 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
HK1039325B (en) 1998-09-18 2006-02-24 Abbott Gmbh & Co. Kg 4-aminopyrrolopyrimidines as kinase inhibitors
UA71945C2 (en) 1999-01-27 2005-01-17 Pfizer Prod Inc Substituted bicyclic derivatives being used as anticancer agents
AU4327600A (en) 1999-04-02 2000-10-23 Du Pont Pharmaceuticals Company Aryl sulfonyls as factor xa inhibitors
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
EP1181296A1 (de) 1999-06-03 2002-02-27 Abbott Laboratories Zelladhäsionshemmende entzündungshemmende verbindungen
CN1390220A (zh) 1999-09-17 2003-01-08 艾博特股份有限两合公司 作为治疗剂的激酶抑制剂
DE60004685T2 (de) * 1999-09-17 2004-07-29 Abbott Gmbh & Co. Kg Pyrazolopyrimidine als arzneimittel
US6632815B2 (en) * 1999-09-17 2003-10-14 Millennium Pharmaceuticals, Inc. Inhibitors of factor Xa
US6921763B2 (en) 1999-09-17 2005-07-26 Abbott Laboratories Pyrazolopyrimidines as therapeutic agents
HUP0203954A2 (hu) 1999-09-17 2003-03-28 Millennium Pharmaceuticals, Inc. Xa faktor inhibitorok
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
MXPA02005106A (es) 1999-11-22 2002-11-07 Smithkline Beecham Plc Compuestos novedosos.
IL150061A0 (en) 1999-12-17 2002-12-01 Ariad Pharma Inc Purine derivatives
US7115589B2 (en) * 1999-12-17 2006-10-03 Ariad Pharmaceuticals, Inc. Purine derivatives
NZ514403A (en) 1999-12-27 2002-10-25 Japan Tobacco Inc Fused-ring compounds and use thereof as drugs
CA2396276A1 (en) 2000-01-07 2001-07-12 Universitaire Instelling Antwerpen Purine derivatives, process for their preparation and use thereof
GB2359081A (en) 2000-02-11 2001-08-15 Astrazeneca Uk Ltd Pharmaceutically active thiazolopyrimidines
WO2001072751A1 (en) 2000-03-29 2001-10-04 Knoll Gesellschaft Mit Beschraenkter Haftung Pyrrolopyrimidines as tyrosine kinase inhibitors
HK1053844A1 (zh) 2000-03-29 2003-11-07 Knoll Gmbh 鉴定tie-2抑制剂的方法
WO2002000651A2 (en) 2000-06-27 2002-01-03 Bristol-Myers Squibb Pharma Company Factor xa inhibitors
JP2002105081A (ja) 2000-07-28 2002-04-10 Nikken Chem Co Ltd 新規チオフェンニ環化合物
WO2002020734A2 (en) 2000-09-08 2002-03-14 Glaxo Group Limited Crystallized cytoplasmic tie2 receptor tyrosine kinase domain and method of determining and designing modulators of the same
US20020146472A1 (en) 2000-11-15 2002-10-10 Chen Kuang Yu Black tea extract for prevention of disease
JP2004517080A (ja) 2000-11-29 2004-06-10 グラクソ グループ リミテッド Ｔｉｅ−２および／またはｖｅｇｆｒ−２の阻害剤として有用なベンゾイミダゾール誘導体
MXPA03008560A (es) 2001-03-22 2004-06-30 Abbot Gmbh & Co Kg Pirazolopirimidinas como agentes terapeuticos.
SE0101322D0 (sv) 2001-04-12 2001-04-12 Astrazeneca Ab Novel compounds
US20030096813A1 (en) 2001-04-20 2003-05-22 Jingrong Cao Compositions useful as inhibitors of GSK-3
WO2003000194A2 (en) 2001-06-21 2003-01-03 Pfizer Inc. Thienopyridine and thienopyrimidine anticancer agents
US20030114467A1 (en) 2001-06-21 2003-06-19 Shakespeare William C. Novel pyrazolo- and pyrrolo-pyrimidines and uses thereof
GB0118479D0 (en) 2001-07-28 2001-09-19 Astrazeneca Ab Novel compounds
AU2002333524A1 (en) 2001-09-11 2003-03-24 Glaxosmithkline K.K. Furo-and thienopyrimidine derivatives as angiogenesis inhibitors
EP1436279B8 (de) 2001-09-21 2008-10-29 Smithkline Beecham Corporation Chemische verbindungen
EP1441725A1 (de) 2001-10-26 2004-08-04 Aventis Pharmaceuticals Inc. Benzimidazole und analoga und ihre verwendung als proteinkinase-hemmer
US7247734B2 (en) 2001-12-21 2007-07-24 Vernalis (Cambridge) Limited 3,4-diarylpyrazoles and their use in the therapy of cancer
TW200306191A (en) 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
BR0308232A (pt) 2002-03-07 2004-12-28 Hoffmann La Roche Inibidores de cinase p38 de piridina e pirimidina bicìclicas

Also Published As

Publication number Publication date
DE60304718D1 (de) 2006-05-24
EP1537112B1 (de) 2006-04-19
AU2003246972A1 (en) 2004-02-23
NO20050418L (no) 2005-04-28
JP2005538118A (ja) 2005-12-15
BR0313078A (pt) 2005-07-12
US20050256140A1 (en) 2005-11-17
IL166521A0 (en) 2006-01-15
DE60304718T2 (de) 2007-04-26
EP1537112A1 (de) 2005-06-08
KR20050067383A (ko) 2005-07-01
AR041189A1 (es) 2005-05-04
CA2494421A1 (en) 2004-02-12
TW200407116A (en) 2004-05-16
MXPA05001389A (es) 2005-04-28
WO2004013141A1 (en) 2004-02-12
US7427616B2 (en) 2008-09-23

Similar Documents

Publication Publication Date Title
DE60304718D1 (de) Kondensierte pyridine und pyrimidine mit tie2 (tek) aktivität
ATE341546T1 (de) 4-trifluormethylpyrazolyl substituierte pyridine und pyrimidine
ATE472536T1 (de) Pyridin- und pyrimidin-derivate
IS6518A (is) Pyridín, pyrimidín, pyrazín og tríazín setin með arýl og notkun þeirra
PL375390A1 (en) 4-trifluoromethylpyrazolyl substituted pyridines and pyrimidines
ATE402705T1 (de) Pyrimidine mit tie2 (tek) aktivität
ATE410429T1 (de) Bicyclische pyridin- und pyrimidininhibitoren von p38-kinase
NO20021520L (no) Substituerte pyridiner og pyridaziner med angiogeneseinhiberende aktivitet
PL370480A1 (en) Aminopyrimidines and pyridines
NO20042676L (no) 3-beta-d-ribofuranolsyltiazolo[4,5-d]pyrimidinnukleosider og anvendelser derav
DK1483247T3 (da) Arylsubstituerede pyrimidiner og anvendelsen deraf
ATE377591T1 (de) Pyrimidinderivate und deren verwendung als cb2- modulatoren
ATE415970T1 (de) Pyrimidine mit tie2 (tek) aktivität
DK1487805T3 (da) Pyrimidinderivater
ATE362313T1 (de) Nicotinsäure-heterocyclyl-amide und analoge pyrimidin-derivate als schädlingsbekämpfungsmittel
DE69837621D1 (de) Substituierte pyrimidine und pyridine als unkrautbekämpfungsmittel
DE602004020486D1 (de) Pyridin-derivate und ihre verwendung als urotensin ii antagonisten
NO20035797L (no) 6-[2-(fosfonometoksy)alkoksy]pyrimidinderivater med antiviral aktivitet
DE69627062D1 (de) Herbizide 2,6-disubstituierte Pyridine und 2,4-disubstituierte Pyrimidine
ATE350370T1 (de) 2-substituierte pyrimidine
ATE458728T1 (de) 2-(pyridin-2-yl)-pyrimidine und ihre verwendung zur bekämpfung von schadpilzen
ZA200500863B (en) Condensed pyridines and pyrimidines with Tie2 (tek) activity.
DE60207280D1 (de) GLYCINSUBSTITUIERTE THIENO[2,3-d]PYRIMIDINE MIT KOMBINIERTER LH- UND FSH-AGONISTISCHER WIRKUNG
DE50106542D1 (de) Substituierte 3,4-dihydro-pyrido[1,2-a]pyrimidine
DE50014992D1 (de) Infrarotabsorber und damit hergestellter thermischer Sensor

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties